Portal de Periódicos da CAPES

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis)

2024; Informa; Volume: 35; Issue: 1 Linguagem: Inglês

10.1080/09546634.2024.2393376

1471-1753

Diego Orsini, Matteo Megna, Chiara Assorgi, Anna Balato, Riccardo Balestri, Nicoletta Bernardini, Alberta Bettacchi, Tommaso Bianchelli, Luca Bianchi, Gionata Buggiani, Martina Burlando, Alexandra Maria Giovanna Brunasso, Giacomo Caldarola, Norma Cameli, Anna Campanati, Elena Campione, Andrea Carugno, Karin Chersi, Andrea Conti, Antonio Costanzo, Emanuele Cozzani, Aldo Cuccia, Domenico D’Amico, Giacomo Dal Bello, Elena DallʼOlio, Paolo Dapavo, Clara De Simone, Eugenia Veronica Di Brizzi, A. Di Cesare, Valentina Dini, Maria Esposito, Enzo Errichetti, Maria Concetta Fargnoli, C. S. Fiorella, A Foti, Zeno Fratton, Francesca Maria Gaiani, Paolo Gisondi, Roberta Giuffrida, Alessandro Giunta, Claudio Guarneri, Agostina Legori, Francesco Loconsole, Piergiorgio Malagoli, Alessandra Narcisi, Matteo Paolinelli, Luca Potestio, Francesca Prignano, Guilherme Rech Cassanego, Ana B. Rossi, Nevena Skroza, Francesca M. Trovato, Marina Venturini, Antonio Giovanni Richetta, Giovanni Pellacani, Annunziata Dattola,

Autoimmune Bullous Skin Diseases

The aim of this multicenter observational study is to report data from real world on the use of bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoriasis. Elderly patients are poorly represented in clinical trials on bimekizumab for plaque psoriasis, and real-world studies are important to guide clinical choices.